The flavonoid Baohuoside-I inhibits cell growth and downregulates survivin and cyclin D1 expression in esophageal carcinoma via β-catenin-dependent signaling

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1149-1156

  Wang, Lifang ^a   Lu, An ^b   Liu, Xiaoxia ^c   Sang, Meixiang ^a   Shan, Baoen ^a   Meng, Fanru ^a   Cao, Qing ^a   Ji, Xin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Province Center for Disease Control and Prevention   (China)

^c HEBEI UNIVERSITY OF ENGINEERING   (China)

Author keywords

catenin; Baohuoside I; Esophageal cancer cells; Nude mouse xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; BAOHUOSIDE I; BETA CATENIN; CYCLIN D1; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA CATENIN GENE; CANCER INHIBITION; CELL LYSATE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; ESOPHAGUS CARCINOMA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; BETA CATENIN; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN D1; DOWN-REGULATION; DRUGS, CHINESE HERBAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLAVONOIDS; GENE EXPRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053156121     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1400     Document Type: Article

References (49)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin 55: 74-108, 2005. (Pubitemid 40372904)
2. Munro AJ: Oesophageal cancer: a view over overviews. Lancet 364: 566-568, 2004.
3. Sant M, Allemani C, Santapuilani M, Knijn A, Marchesi F and Capocaccia R: EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45: 931-991, 2009.
4. Zou XN, Chen WQ, Zhang SW, Li LD, Lu FZ and Chen YH: An analysis of esophageal cancer incidence and mortality from 30 cancer registries in China, 1998-2002. China Cancer 161: 142-146, 2007.
5. Stoner GD and Gupta A: Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22: 1737-1746, 2001. (Pubitemid 33064837)
6. Besharat S, Jabbari A, Semnani S, Keshtkar A and Marjani J: Inoperable esophageal cancer and outcome of palliative care. World J Gastroenterol 14: 3725-3728, 2009.
7. Alibakhshi A, Aminian A, Mirsharifi R, Jahangiri Y, Dashti H and Karimian F: The effect of age on the outcome of esophageal cancer surgery. Ann Thorac Med 4: 71-74, 2009.
8. Cragg GM, Grothaus PG and Newman DJ: Impact of natural products on developing new anti-cancer agents. Chem Rev 109: 3012-3043, 2009.
9. Koehn FE and Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206-220, 2005. (Pubitemid 40372555)
10. Mann J: Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2: 143-148, 2002.
11. National Committee of Pharmacopeia: Pharmacopoeia of the People's Republic of China, Chemical Industry Publishing Company, Beijing, p181, 2005 (In Chinese).
12. Itokawa H, Xu JP and Takeya K: Studies on chemical constituents of an antitumor fraction from Periploca sepium. V. Structures of new pregnane glycosides, periplocosides J, K, F and O. Chem Pharm Bull 36: 4441-4446, 1998.
13. Zhang J, Shan BE and Liu GS: Apoptosis induced by ethyl acetate extract from Cortex periplocae in human breast cancer cell line MCF-7. Tumor 26: 418-421, 2006 (In Chinese).
14. Zhao LM, Shan BE, Ai J, Ren FZ and Lian YS: Effects of periplocin from Cortex periplocae on proliferation of human esophageal carcinoma cells TE-13 and related mechanisms. Tumor 28: 203-206, 2008 (In Chinese). (Pubitemid 351486128)
15. Wang LF, Shan BE, Liu LH, Ren FZ and Shan TQ: Effect of Baohuoside-I from Cortex periplocae on proliferation and apoptosis of esophageal carcinoma cells. Tumor 29: 123-126, 2009 (In Chinese).
16. Lv J, Cao XF, Ji L, Zhu B, Tao L and Wang DD: Association of Wnt1/β-catenin with clinical pathological characteristics and prognosis of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers 14: 363-369, 2010.
17. DasGupta R, Kaykas A, Moon RT and Perrimon N: Functional genomic analysis of the Wnt-wingless signaling pathway. Science 308: 826-833, 2005. (Pubitemid 40629258)
18. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y and Sham JS: Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br J Cancer 94: 108-114, 2006. (Pubitemid 43088549)
19. Tetsu O and Frank MC: β-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999. (Pubitemid 29180374)
20. Kudo J, Nishiwaki T, Haruki N, et al: Aberrant nuclear localization of β-catenin without genetic alterations in β-catenin or Axin genes in esophageal cancer. World J Surg Oncol 5: 21-29, 2007.
21. Ji L, Cao XF, Wang HM, et al: Expression level of beta-catenin is associated with prognosis of esophageal carcinoma. World J Gastroenterol 13: 2622-2625, 2007. (Pubitemid 46938836)
22. Liu LH, Wang SJ, Shan BE, Shao L, Sato A and Kawamura K: IL-27-mediated activation of natural killer cells and inflammation produce antitumor effects for human esophageal carcinoma cells. Scand J Rheumatol 68: 22-29, 2008. (Pubitemid 351798398)
23. He BC, Chen L, Zuo GW, et al: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16: 2235-2245, 2010.
24. Luo X, Chen J, Song WX, et al: Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 88: 1264-1277, 2008.
25. Su Y, Luo X, He BC, et al: Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis 26: 599-610, 2009.
26. Utsunomiya T, Doki Y, Takemoto H, et al: Correlation of beta-catenin and cyclin D1 expression in colon cancers. Oncology 61: 226-233, 2001. (Pubitemid 34701538)
27. Thevenod F and Chakraborty PK: The role of Wnt/beta-catenin signaling in renal carcinogenesis: lessons from cadmium toxicity studies. Curr Mol Med 10: 387-404, 2010.
28. Doucas H, Garcea G, Neal CP, Manson MM and Berry DP: Changes in the Wnt signalling pathway in gastrointestinal cancers and their prognostic significance. Eur J Cancer 41: 365-379, 2005. (Pubitemid 40187207)
29. Wu T, Yang X, Zeng X and Eslick GD: Traditional Chinese medicinal herbs in the treatment of patients with esophageal cancer: a systematic review. Gastroenterol Clin North Am 38: 153-167, 2009.
30. Nelson WJ and Nusse R: Convergence of Wnt, β-catenin, and cadherin pathways. Science 303: 1483-1487, 2004. (Pubitemid 38314410)
31. Giles RH, Van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003. (Pubitemid 36627817)
32. Situ DR, Hu Y, Zhu ZH, Wang J, Long H and Rong TH: Prognostic relevance of β-catenin expression in T2-3N0M0 esophageal squamous cell carcinoma. World J Gastroenterol 16: 5195-5202, 2010.
33. Yang F, Zeng Q, Yu G, Li S and Wang CY: Wnt/beta-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCC. Cell Signal 18: 679-687, 2006. (Pubitemid 43113298)
34. Goto M, Mitra RS, Liu M, et al: Rap1 stabilizes beta-catenin and enhances beta-catenin-dependent transcription and invasion in squamous cell carcinoma of the head and neck. Clin Cancer Res 16: 65-76, 2010.
35. Tsai YP, Yang MH, Huang CH, et al: Interaction between HSP60 and beta-catenin promotes metastasis. Carcinogenesis 30: 1049-1057, 2009.
36. Morin PJ, Sparks AB, Korinek V, et al: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275: 1787-1790, 1997. (Pubitemid 27136715)
37. Dilek FH, Topak N, Tokyol C, Akbulut G and Dilek ON: β-catenin and its relation to VEGF and cyclin D1 expression in pT3 recto-sigmoid cancers. Turk J Gastroenterol. 21: 365-371, 2010.
38. Saifo MS, Rempinski DR Jr, Rustum YM and Azrak RG: Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. Mol Cancer 9: 310-320, 2010.
39. Shan BE, Wang MX and Li RQ: Quercetin inhibits human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/β-catenin signaling pathway. Cancer Invest 27: 604-612, 2009.
40. Park CH, Chang JY, Hahm ER, Park S, Kim HK and Yang CH: Quercetin, a potent inhibitor against β-catenin/Tcf signaling in SW480 colon cancer cells. Biochem Biophys Res Commun 328: 227-234, 2005. (Pubitemid 40164659)
41. Song S, Krishnan K, Liu K and Bresalier RS: Polyphenon E inhibits the growth of human Barrett's and aerodigestive adenocarcinoma cells by suppressing cyclin D1 expression. Clin Cancer Res 15: 622-631, 2009.
42. Behrens J: Control of β-catenin signaling in tumor development. Ann NY Acad Sci 910: 21-33, 2000.
43. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: cyclin D1: normal and abnormal functions. Endocrinology 145: 5439-5447, 2004. (Pubitemid 39564581)
44. Lin DC, Du XL and Wang MR: Protein alterations in ESCC and clinical implications: a review. Dis Esophagus 22: 9-20, 2004.
45. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997. (Pubitemid 27353455)
46. Yie SM, Lou B, Ye SR, et al: Clinical significance of detecting survivin-expressing circulating cancer in patients with non-small cell lung cancer. Lung Cancer 63: 284-290, 2009.
47. Vallbohmer D, Kuhn E, Warnecke-Eberz U, et al: Failure in down-regulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 9: 681-690, 2008.
48. Kim PJ, Plescia J, Clevers H, Fearon ER and Altieri DC: Survivin and molecular pathogenesis of colorectal cancer. Lancet 362: 205-209, 2003. (Pubitemid 36859937)
49. Ma H, Nguyen C, Lee KS and Kahn M: Differential role for the coactivators CBP and p300 on TCF/β-catenin-mediated survivin gene expression. Oncogene 24: 3619-3631, 2005. (Pubitemid 40756231)